1. Medtech Insight
  2. >>Policy & Regulation

Cost-Center Controversy: CT, MRI Payments Down In Inpatient Rule

CMS’ decision to rely on data from individual CT and MRI cost centers, rather than from a general radiology line, is derided by imaging equipment makers who say it does not account for the flawed approach employed by some hospitals to report capital equipment costs. Meanwhile, device makers applaud the agency’s application of a specific cost line for implantable devices.

CMS overruled objections from medical imaging companies and provider groups in moving ahead with plans to factor in distinct cost reports from hospitals for computed tomography and MRI scans into inpatient reimbursement calculations next year, which will reduce payments for those technologies.

The agency finalized a policy to implement separate hospital cost-to-charge ratios for the advanced imaging scans in its fiscal year 2014 inpatient prospective payment system (IPPS) rule issued Aug. 2....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.